EASL guidance recommends resmetirom or semaglutide for non-cirrhotic MASH with fibrosis stages 2-3. A joint EASL-EASD-EASO guideline recommends pharmacotherapy with resmetirom or semaglutide for adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis stages 2-3. The guidance advises using non-invasive tests to identify high-risk patients and individualizing therapy based on cardiometabolic profiles. Guideline, Journal of hepatology, 1 Dec 2026.

Mit Resmetirom ist erstmals ein zugelassenes Arzneimittel zur Behandlung der Fettlebererkrankung MASH auf den Markt gekommen. Es ist ein Agonist am Schildd...

A new study suggests that Resmetirom may do more than treat fatty liver disease — it could also help stop liver cancer from developing.

Metabolic dysfunction-associated steatotic liver disease (MASLD) and its severe subgroup metabolic dysfunction-associated steatohepatitis (MASH) have become a global epidemic and are driven by chronic overnutrition and multiple genetic susceptibility factors. The physiological outcomes include hepatocyte death, liver inflammation and cirrhosis. The first therapeutic for MASLD and MASH, resmetirom, has recently been approved for clinical use and has energized this therapeutic space. However, there is still much to learn in clinical studies of MASH, such as the scale of placebo responses, optimal trial end points, the time required for fibrosis reversal and side effect profiles. This Review introduces aspects of disease pathogenesis related to drug development and discusses two main therapeutic approaches. Thyroid hormone receptor-β agonists, such as resmetirom, as well as fatty acid synthase inhibitors, target the liver and enable it to function within a toxic metabolic environment

In 2023, the medical terminology for Nonalcoholic Fatty Liver Disease (NAFLD) and NA SteatoHepatitis (NASH) was updated to Metabolic Dysfunction-Associated SteatoticLiver Disease (MASLD) and MA Steat...

npj Gut and Liver - Reviewing MAESTRO-NASH and the implications for hepatology and health systems in implementation/accessibility of Resmetirom

Nuevos biomarcadores y terapias como resmetirom y semaglutida transforman el diagnóstico y tratamiento de la MASLD, una enfermedad hepática que afecta al 30 % de la población ...

A new study suggests that Resmetirom may do more than treat fatty liver disease — it could also help stop liver cancer from developing. Resmetirom, a drug approved by the U.S. Food and Drug Administration (FDA) to treat metabolic dysfunction associated fatty liver disease (MAFLD), may offer benefits beyond reducing liver fat and fibrosis, according to a new study published in the journal Hepatology. Researchers found the drug may also help prevent and suppress liver cancer linked to fatty liver disease. The study was conducted by a team from the Department of Pathology, School of Clinical Medicine, LKS Faculty of Medicine of the University of Hong Kong (HKUMed), in collaboration with the HKU State Key Laboratory of Liver Research. Link between fatty liver and liver cancer Hepatocellular carcinoma (HCC) ranks as the sixth most common cancer worldwide and the third leading cause of cancer-related death. As obesity, diabetes, and metabolic syndrome become more common, fatty liver disease and liver cancer driven by metabolic disorders are playing an increasingly important role in liver cancer development. Published data show that about 3% of people with fatty liver disease develop liver cancer each year. The burden is especially high in Asia, where an...

O descubrimento do CiMUS sobre o Resmetiron permitirá desenvolver terapias dirixidas especificamente contra esta enfermidade no futuro

This Review summarizes the pathogenesis, epidemiology, diagnosis, treatment, and prognosis for adults with metabolic dysfunction–associated steatotic liver disease.

People who used resmetirom (Rezdiffra) in a late-stage clinical trial experienced both MASH resolution and fibrosis improvement.